FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Pediatrics | Pharmaceuticals